RxDoctor Payments Data

Amanda Strom

Optometrist · Overland Park, KSNPI 1174534051

Payments from drug & device makers

$2,797in general payments, 2019–2025

Across 85 payments — averaging $32.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Sun Pharmaceutical Industries Inc.$344
  • Alcon$189
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$184
  • Optos, Inc.$127
  • Aerie Pharmaceuticals, Inc.$119
  • plus $234 from 8 others

What the payments were for

  • Consulting fees$1,22544%
  • Food & beverage$1,46752%
  • Entertainment$1054%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,797 in reported general payments places this provider in the 85th percentile of 567 optometrist providers in Kansas.

See all optometrist providers in Kansas

Medicare billing

Part B allowed, 2024
$87,219
Medicare patients
398
Services billed
1,225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine68$69,490
LumiganBimatoprost66$32,336
CombiganBrimonidine Tartrate/Timolol48$18,883
XiidraLifitegrast13$15,099
Cyclosporine11$8,551
RocklatanNetarsudil Mesylat/Latanoprost17$7,301
SimbrinzaBrinzolamide/Brimonidine Tart29$5,912
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat251$3,857
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$2,816
Latanoprost196$2,559
Travoprost12$2,400
Timolol Maleate162$2,151
Prednisolone Acetate51$1,941
Brimonidine Tartrate70$1,924
Dorzolamide Hcl46$1,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$1,601$120,709182 claims
Bausch & Lomb Americas Inc.Xiidra$53$15,09913 claims
Aerie Pharmaceuticals, Inc.Rocklatan$119$7,30117 claims
AlconSimbrinza$189$5,91229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 567 optometrist providers in Kansas.

Other optometrist in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →